In adults with BMI ≥27 kg/m<sup>2</sup> and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 37931265.
- Also identified by DOI 10.7326/J23-0089.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Garvey WT, Frias JP, Jastreboff AM, et al; SURMOUNT-2 investigators. <b>Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.</b> Lancet. 2023;402:613-626. 37385275.
Medical subject headings
- Diabetes Mellitus, Type 2